File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Radiotherapy in the management of glottic squamous cell carcinoma

TitleRadiotherapy in the management of glottic squamous cell carcinoma
Authors
KeywordsExtranodal extension
Glottis
Head and neck
Radiotherapy
Squamous cell carcinoma
Issue Date2020
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0347
Citation
Head and Neck, 2020 How to Cite?
AbstractIntroduction: Our purpose is to review the role radiotherapy (RT) in the treatment of glottic squamous cell carcinoma (SCC). Methods: A concise review of the pertinent literature. Results: RT cure rates are Tis‐ T1N0, 90% to 95%; T2N0, 70% to 80%; low‐volume T3‐T4a, 65% to 70%. Concomitant cisplatin is given for T3‐T4a SCCs. Severe complications occur in 1% to 2% for Tis‐T2N0 and 10% for T3‐T4a SCCs. Patients with high‐volume T3‐T4 SCCs undergo total laryngectomy, neck dissection, and postoperative RT. Those with positive margins and/or extranodal extension receive concomitant cisplatin. The likelihood of local‐regional control at 5 years is 85% to 90%. Severe complications occur in 5% to 10%. Conclusions: RT is a good treatment option for patients with Tis‐T2N0 and low‐volume T3‐T4a glottic SCCs. Patients with higher volume T3‐T4 cancers are best treated with surgery and postoperative RT.
Persistent Identifierhttp://hdl.handle.net/10722/287146
ISSN
2020 Impact Factor: 3.147
2020 SCImago Journal Rankings: 1.012
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMendenhall, WM-
dc.contributor.authorStrojan, P-
dc.contributor.authorLee, AWM-
dc.contributor.authorRinaldo, A-
dc.contributor.authorEisbruch, A-
dc.contributor.authorNg, WT-
dc.contributor.authorSmee, R-
dc.contributor.authorFerlito, A-
dc.date.accessioned2020-09-22T02:56:29Z-
dc.date.available2020-09-22T02:56:29Z-
dc.date.issued2020-
dc.identifier.citationHead and Neck, 2020-
dc.identifier.issn1043-3074-
dc.identifier.urihttp://hdl.handle.net/10722/287146-
dc.description.abstractIntroduction: Our purpose is to review the role radiotherapy (RT) in the treatment of glottic squamous cell carcinoma (SCC). Methods: A concise review of the pertinent literature. Results: RT cure rates are Tis‐ T1N0, 90% to 95%; T2N0, 70% to 80%; low‐volume T3‐T4a, 65% to 70%. Concomitant cisplatin is given for T3‐T4a SCCs. Severe complications occur in 1% to 2% for Tis‐T2N0 and 10% for T3‐T4a SCCs. Patients with high‐volume T3‐T4 SCCs undergo total laryngectomy, neck dissection, and postoperative RT. Those with positive margins and/or extranodal extension receive concomitant cisplatin. The likelihood of local‐regional control at 5 years is 85% to 90%. Severe complications occur in 5% to 10%. Conclusions: RT is a good treatment option for patients with Tis‐T2N0 and low‐volume T3‐T4a glottic SCCs. Patients with higher volume T3‐T4 cancers are best treated with surgery and postoperative RT.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0347-
dc.relation.ispartofHead and Neck-
dc.subjectExtranodal extension-
dc.subjectGlottis-
dc.subjectHead and neck-
dc.subjectRadiotherapy-
dc.subjectSquamous cell carcinoma-
dc.titleRadiotherapy in the management of glottic squamous cell carcinoma-
dc.typeArticle-
dc.identifier.emailLee, AWM: awmlee@hkucc.hku.hk-
dc.identifier.emailNg, WT: ngwt1@hkucc.hku.hk-
dc.identifier.authorityLee, AWM=rp02056-
dc.identifier.authorityNg, WT=rp02671-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/hed.26419-
dc.identifier.pmid32896071-
dc.identifier.scopuseid_2-s2.0-85090299180-
dc.identifier.hkuros314400-
dc.identifier.isiWOS:000566745100001-
dc.publisher.placeUnited States-
dc.identifier.issnl1043-3074-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats